Oral salmon calcitonin improves fasting and postprandial glycemic control in lean healthy rats

Hormone and Metabolic Research

Volumn 44, Issue 2, 2012, Pages 130-134

  Feigh, M ^a   Nielsen, R H ^a   Hansen, C ^a   Henriksen, K ^a   Christiansen, C ^a   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

antidiabetic drug; glycemic control; salmon calcitonin; type 2 diabetes

Indexed keywords

INSULIN; SALCATONIN;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CALCITONIN; EATING; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; MALE; POSTPRANDIAL PERIOD; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84857060956     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1298027     Document Type: Article

References (34)

1. Levitzky Y S, Pencina M J, DAgostino R B, Meigs J B, Murabito J M, Vasan R S, Fox C S. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol: 2008; 51 264 270
2. Peter R, Okoseime O E, Rees A, Owens D R. Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol: 2009; 7 68 74
3. Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care: 2010; 33 2211 2216
4. Israili Z H. Advances in the treatment of type 2 diabetes mellitus. Am J Ther: 2011; 18 117 152
5. Blonde L. State of diabetes care in the United States. Am J Manag Care: 2007; 13 02 S36 S40 (Pubitemid 46651159)
6. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med: 2009; 76 05 S4 S11
7. Gedulin B R, Jodka C M, Herrmann K, Young A A. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul Pept: 2006; 137 121 127 (Pubitemid 44841988)
8. Roth J D, Hughes H, Kendall E, Baron A D, Anderson C M. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology: 2006; 147 5855 5864 (Pubitemid 44833502)
9. Ryan G, Briscoe T A, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther: 2009; 2 203 214
10. Malkov D, Angelo R, Wang H Z, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv: 2005; 2 191 197 (Pubitemid 40488628)
11. Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther: 2008; 84 468 474
12. Reidelberger R D, Kelsey L, Heimann D. Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol: 2002; 282 R1395 R1404 (Pubitemid 34664526)
13. Wielinga P Y, Alder B, Lutz T A. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol Behav: 2007; 91 212 217 (Pubitemid 46770799)
14. Chelikani P K, Haver A C, Reidelberger R D. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol: 2007; 293 R1798 R1808 (Pubitemid 350085656)
15. Henriksen K, Bay-Jensen A C, Christiansen C, Karsdal M A. Oral salmon calcitonin - pharmacology in osteoporosis. Expert Opin Biol Ther: 2010; 10 1617 1629
16. Karsdal M A, Henriksen K, Bay-Jensen A C, Molloy B, Arnold M, John M R, Byrjalsen I, Azria M, Riis B J, Qvist P, Christiansen C. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol: 2011; 51 460 471
17. Buclin T, Cosma R M, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res: 2002; 17 1478 1485 (Pubitemid 34803831)
18. Bagger Y Z, Tanko L B, Alexandersen P, Karsdal M A, Olson M, Mindeholm L, Azria M, Christiansen C. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone: 2005; 37 425 430 (Pubitemid 41160502)
19. Tanko L B, Bagger Y Z, Alexandersen P, Devogelaer J P, Reginster J Y, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res: 2004; 19 1531 1538 (Pubitemid 41094356)
20. Feigh M, Henriksen K, Andreassen K V, Hansen C, Henriksen J E, Beck-Nielsen H, Christiansen C, Karsdal M A. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab: 2011; 13 911 920
21. Roth J D, Roland B L, Cole R L, Trevaskis J L, Weyer C, Koda J E, Anderson C M, Parkes D G, Baron A D. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA: 2008; 105 7257 7262 (Pubitemid 351754465)
22. Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia: 1985; 28 412 419 (Pubitemid 15018832)
23. Twery M J, Obie J F, Cooper C W. Ability of calcitonins to alter food and water consumption in the rat. Peptides: 1982; 3 749 755 (Pubitemid 13171612)
24. Morley J E, Flood J F. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci: 1987; 41 2157 2165 (Pubitemid 18032328)
25. Chelikani P K, Haver A C, Reidelberger R D. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol: 2007; 293 R1798 R1808 (Pubitemid 350085656)
26. Pilon G, Ruzzin J, Rioux L E, Lavigne C, White P J, Froyland L, Jacques H, Bryl P, Beaulieu L, Marette A. Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat-fed rats. Metabolism: 2011; 60 1122 1130
27. Trevaskis J L, Turek V F, Wittmer C, Griffin P S, Wilson J K, Reynolds J M, Zhao Y, Mack C M, Parkes D G, Roth J D. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology: 2010; 151 5657 5668
28. Baskin D G, Figlewicz L D, Seeley R J, Woods S C, Porte D Jr, Schwartz M W. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res: 1999; 848 114 123 (Pubitemid 30001660)
29. Young A A, Wang M W, Gedulin B, Rink T J, Pittner R, Beaumont K. Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism: 1995; 44 1581 1589 (Pubitemid 26102598)
30. Greeley G H Jr, Cooper C W, Jeng Y J, Eldridge J C, Thompson J C. Intracerebroventricular administration of calcitonin enhances glucose-stimulated release of insulin. Regul Pept: 1989; 24 259 268 (Pubitemid 19069679)
31. Kapitza C, Zijlstra E, Heinemann L, Castelli M C, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care: 2010; 33 1288 1290
32. Potes C S, Turek V F, Cole R L, Vu C, Roland B L, Roth J D, Riediger T, Lutz T A. Noradrenergic neurons of the area postrema mediate amylins hypophagic action. Am J Physiol Regul Integr Comp Physiol: 2010; 299 R623 R631
33. Potes C S, Lutz T A. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav: 2010; 100 511 518
34. Pilon G, Ruzzin J, Rioux L E, Lavigne C, White P J, Froyland L, Jacques H, Bryl P, Beaulieu L, Marette A. Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat-fed rats. Metabolism: 2011; 60 1122 1130